No Cover Image

Journal article 634 views

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer

European Urology

Swansea University Author: John Wagstaff

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1016/j.eururo.2017.02.010

Published in: European Urology
ISSN: 03022838
Published: 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa34579
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2017-07-11T12:06:26Z
last_indexed 2018-02-09T05:24:51Z
id cronfa34579
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2017-09-15T14:36:42.3076289</datestamp><bib-version>v2</bib-version><id>34579</id><entry>2017-07-09</entry><title>CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-07-09</date><deptcode>SGMED</deptcode><abstract/><type>Journal Article</type><journal>European Urology</journal><publisher/><issnPrint>03022838</issnPrint><keywords/><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-12-31</publishedDate><doi>10.1016/j.eururo.2017.02.010</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2017-09-15T14:36:42.3076289</lastEdited><Created>2017-07-09T12:27:06.4744384</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Bernard</firstname><surname>Escudier</surname><order>1</order></author><author><firstname>Padmanee</firstname><surname>Sharma</surname><order>2</order></author><author><firstname>David F.</firstname><surname>McDermott</surname><order>3</order></author><author><firstname>Saby</firstname><surname>George</surname><order>4</order></author><author><firstname>Hans J.</firstname><surname>Hammers</surname><order>5</order></author><author><firstname>Sandhya</firstname><surname>Srinivas</surname><order>6</order></author><author><firstname>Scott S.</firstname><surname>Tykodi</surname><order>7</order></author><author><firstname>Jeffrey A.</firstname><surname>Sosman</surname><order>8</order></author><author><firstname>Giuseppe</firstname><surname>Procopio</surname><order>9</order></author><author><firstname>Elizabeth R.</firstname><surname>Plimack</surname><order>10</order></author><author><firstname>Daniel</firstname><surname>Castellano</surname><order>11</order></author><author><firstname>Howard</firstname><surname>Gurney</surname><order>12</order></author><author><firstname>Frede</firstname><surname>Donskov</surname><order>13</order></author><author><firstname>Katriina</firstname><surname>Peltola</surname><order>14</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>15</order></author><author><firstname>Thomas C.</firstname><surname>Gauler</surname><order>16</order></author><author><firstname>Takeshi</firstname><surname>Ueda</surname><order>17</order></author><author><firstname>Huanyu</firstname><surname>Zhao</surname><order>18</order></author><author><firstname>Ian M.</firstname><surname>Waxman</surname><order>19</order></author><author><firstname>Robert J.</firstname><surname>Motzer</surname><order>20</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2017-09-15T14:36:42.3076289 v2 34579 2017-07-09 CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2017-07-09 SGMED Journal Article European Urology 03022838 31 12 2017 2017-12-31 10.1016/j.eururo.2017.02.010 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2017-09-15T14:36:42.3076289 2017-07-09T12:27:06.4744384 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Bernard Escudier 1 Padmanee Sharma 2 David F. McDermott 3 Saby George 4 Hans J. Hammers 5 Sandhya Srinivas 6 Scott S. Tykodi 7 Jeffrey A. Sosman 8 Giuseppe Procopio 9 Elizabeth R. Plimack 10 Daniel Castellano 11 Howard Gurney 12 Frede Donskov 13 Katriina Peltola 14 John Wagstaff 15 Thomas C. Gauler 16 Takeshi Ueda 17 Huanyu Zhao 18 Ian M. Waxman 19 Robert J. Motzer 20
title CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
spellingShingle CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
John Wagstaff
title_short CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
title_full CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
title_fullStr CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
title_full_unstemmed CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
title_sort CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 Bernard Escudier
Padmanee Sharma
David F. McDermott
Saby George
Hans J. Hammers
Sandhya Srinivas
Scott S. Tykodi
Jeffrey A. Sosman
Giuseppe Procopio
Elizabeth R. Plimack
Daniel Castellano
Howard Gurney
Frede Donskov
Katriina Peltola
John Wagstaff
Thomas C. Gauler
Takeshi Ueda
Huanyu Zhao
Ian M. Waxman
Robert J. Motzer
format Journal article
container_title European Urology
publishDate 2017
institution Swansea University
issn 03022838
doi_str_mv 10.1016/j.eururo.2017.02.010
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
published_date 2017-12-31T03:42:54Z
_version_ 1763751991261003776
score 11.013148

Similar Items